TB Screening Improves Preventive Therapy Uptake — TB SCRIPT  

HIV Clinical Trial

Official title: TB Screening Improves Preventive Therapy Uptake Trial

Status Recruiting

Clinical Trial Summary

HIV-infected people have an increased risk of developing active tuberculosis (TB). To reduce the burden of TB among people living with HIV (PLHIV), the World Health Organization (WHO) recommends systematic TB screening followed by 1) confirmatory TB testing for all those who screen positive and 2) TB preventive therapy (TPT) for all TPT-eligible PLHIV who screen negative. The objective of the TB Screening Improves Preventive Therapy Uptake (TB SCRIPT) trial is to determine whether TB screening based on C-reactive protein (CRP) levels, measured using a rapid and low-cost point-of-care (POC) assay, improves TPT uptake and clinical outcomes of PLHIV, relative to symptom-based TB screening.

Clinical Trial Description

The overall objective of the TB SCRIPT trial is to evaluate the effectiveness and cost-effectiveness of POC CRP-based TB screening, which is the next step required for successful scale-up of both systematic TB screening and TPT. The study's central hypothesis is that compared to symptom-based TB screening, a TB screening strategy based on CRP levels measured at the point-of-care will improve TPT uptake, thereby reducing TB incidence and its associated mortality among PLHIV. To test this hypothesis, the investigators will conduct an individual randomized control trial enrolling PLHIV presenting to clinics in Uganda for routine antiretroviral therapy (ART) initiation. Eligible participants will be randomized to either POC CRP-based TB screening (intervention arm) or symptom-based TB screening (control arm). In both arms, screen-positive participants will undergo confirmatory TB testing; participants found to have prevalent TB will be initiated on standard TB treatment. In both arms, screen-negative participants will be assessed for TPT eligibility; TPT-eligible participants will be initiated on standard TPT. All participants will be followed for 2 years. ;

Related Conditions & MeSH terms

• HIV
• Latent Tuberculosis
• Tuberculosis
• Tuberculosis Prevention

• NCT number: NCT04557176
• Study type: Interventional
• Source: University of California, San Francisco
• Contact: Christina Yoon, MD
• Phone: +1 628-206-3514
• Email: Christina.Yoon@ucsf.edu
• Status: Recruiting
• Phase: N/A
• Start date: November 16, 2020
• Completion date: March 15, 2025